The Real Risks of Psychedelics

In this five minute Big Think talk, Johns Hopkins psychopharmacologist Dr. Matthew Johnson takes on a common critique of psychedelic research: that psychedelics are too dangerous to use as medical treatments. Johnson argues that every medical intervention carries risk, so the real question is what those risks are and how to minimize them. He walks through comparative harm data, the history of mid-century psychedelic research, and the conditions that separate riskier use from safer use.

What the comparative harm data show

Johnson points to research in which experts rank-ordered the harms of a wide range of psychoactive compounds, legal and illegal, to the user and to society. He says the results consistently bear little relationship to legal status: tobacco and alcohol land near the top of the harm list, while psilocybin mushrooms rank at the bottom among major psychoactive compounds for harm to self and others. LSD sits in a similarly low position. Psylopedia covers both substances in more detail: psilocybe cubensis and LSD.

Physical safety and low addiction potential

"Psychedelics are really freakishly physically safe for most people," Johnson says. There is no known lethal overdose amount for psilocybin or LSD, and classic psychedelics are not addictive in the way that produces compulsive craving, though he notes they can still be misused in ways that harm the person.

Why the guide and the setting matter

The factor Johnson returns to most is context. He says risk drops when someone uses a psychedelic with a trusted, sober guide present, a controlled dose, and a safe environment, closer to the structure of clinical research than an unsupervised setting where a person also has to worry about their own safety around others. This is the same principle Psylopedia covers as set and setting; see the set and setting guide for more on how inner and outer context shapes an experience.

Separating real risk from urban legend

Johnson pushes back on inherited myths, including the claim that teenagers commonly stared into the sun and went blind while on LSD; he says there is no credible evidence this ever happened. At the same time, he does not minimize what is real: a difficult experience, a "bad trip," is a genuine and documented phenomenon, even if relatively rare, and on occasion people have been injured or have died during one, usually because panic led to a fall or to wandering into traffic. Psylopedia's safety and harm reduction guide covers this territory further.

A cautionary history

Some of the most severe outcomes Johnson describes trace back to research conducted between the 1950s and early 1970s, not to psychedelics themselves. He describes trials in which participants were given large, unannounced doses, in one case 800 micrograms of LSD in an alcoholism study, and were sometimes confined to padded rooms or restrained to a hospital bed. Under those conditions, Johnson says, people sometimes had experiences that looked like psychosis and felt, temporarily, like they were "going crazy." His point: today's clinical protocols, built around informed consent, a trusted presence, and a safe setting, exist specifically to prevent that outcome.

The bigger picture

Johnson frames psychedelic research as still developing, with promise for understanding what supports mental health and how disorders might be prevented, alongside real, documented risks. He is explicit that this is not encouragement to use psychedelics casually. The evidence base for psychedelic-assisted therapy remains investigational, and his closing argument is about proportion: the dangers are real, but in his assessment far less prevalent than the harms of more commonly used legal substances.

Key takeaways

• ●Every medical intervention and psychoactive compound carries risk, Johnson argues; the useful question is what that risk looks like and how to reduce it.
• ●Expert harm-ranking studies place tobacco and alcohol near the top of the harm list and psilocybin and LSD near the bottom, with little relation to legal status.
• ●Neither psilocybin nor LSD has a known lethal overdose amount, and classic psychedelics do not produce the compulsive craving associated with addiction.
• ●A sober guide, a controlled dose, and a safe environment are the biggest factors separating riskier use from safer use, in Johnson's account.
• ●The bad trip is real and documented, though relatively rare; accidents and deaths have occurred when panic led someone to fall or wander into traffic.
• ●The claim that LSD commonly caused teenagers to go blind from staring at the sun has no credible supporting evidence, per Johnson.
• ●Some of the most disturbing historical outcomes came from 1950s to 1970s research that gave large, unannounced doses under coercive conditions, not from the substances alone.
• ●Johnson frames psychedelic-assisted therapy as promising but still investigational, and stresses the risks are real even as he argues they are less prevalent than those of other widely used compounds.